Denagard Logo

Denagard® (tiamulin hydrogen fumarate)

Reduce the impact of two costly enteric diseases
Hemicell logo

Hemicell® (β-mannanase)

β-Mannans: the problem component in soybean meal
Kavault logo

Kavault® (Avilamycin)

Reduce the incidence and overall severity of E. coli scours
paylean logo

Paylean® (Ractopamine hydrochloride)

The choice for improved late-finishing performance and profitability
pulmotil logo

Pulmotil® (tilmicosin)

Control respiratory disease associated with Actinobacillus pleuropneumoniae or Pasteurella multocida
pulmotil AC logo

Pulmotil® AC (tilmicosin phosphate)

Go with the flow to help control swine respiratory disease (SRD)*
Skycis Logo

Skycis® (Narasin)

Ionophores: Innovation for a productive future
Tylan® Injection

Tylan® Injection

Effective at treating swine arthritis* in valuable breeding animals and finishers
Tylan® Logo

Tylan® Premix (Tylosin phosphate)

Proven control of ileitis* for dependable, reliable results

Tylan® Soluble (Tylosin tartrate)

Effective control of ileitis

Kavault logo
Kavault® (Avilamycin)

Reduce the incidence and overall severity of E. coli scours

Kavault is a first-in-class antimicrobial proven to reduce the incidence and overall severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs, during the phase when pigs are most at risk.

E.coli prevalence and impact
Pathogenic E. coli is costly and prevalent in the swine industry. One of the most important causes of post-weaning diarrhea (PWD) in pigs, it ranks among the most common diseases overall in global swine production.1 A major source of frustration and worry, E. coli costs producers in prevention, diagnosis, treatment, mortality, and reduced performance.

Post-weaning diarrhea
At the post-weaning stage, pigs are at risk of E. coli exposure from common conditions like transport, relocation, commingling, loss of maternal antibodies, and change to a solid diet. Clinical signs of E. coli typically appear 5-15 days after weaning and can last for 21 days or more. During this time, the disease can significantly affect herd health and performance.2

Avilamycin overview
Avilamycin, the active ingredient in Kavault, is a first-in-class orthosomycin antibiotic. Developed exclusively for use in food animals, it has never been used in humans and is defined as non-medically important by FDA Guidance 152.3 Avilamycin's animal use only profile aligns with responsible antibiotic use. Avilamycin also has established maximum residue limits with CODEX and the EU, and is only available with a veterinary feed directive (VFD).

Important Safety Information

The label contains complete use information, including cautions and warnings. Always read, understand, and follow the label and use directions.

Caution: Federal law restricts medicated feed containing this veterinary feed directive drug to use by or on the order of a licensed veterinarian.

  • No withdrawal period required when fed according to the label.
  • To assure responsible antimicrobial drug use in pigs, do not administer to pigs 14 weeks of age or older or for more than a lifetime total of 42 days.
  • VFD expiration date must not exceed 90 days from the date of issuance. VFDs for avilamycin shall not be refilled.
  • Avilamycin has not been demonstrated to be effective in pigs showing clinical signs of diarrhea prior to the start of medication.
  • Avoid inhalation, oral exposure, and direct contact with skin or eyes.

Directions for Use

Feed at 73 grams avilamycin per ton of Type C medicated feed (80 ppm) as the sole ration for 21 consecutive days. The veterinarian may direct feeding for up to a total of 42 consecutive days, based on clinical assessment. Feed to pigs that are at risk of developing, but net yet showing sins of diarrhea in the presence of pathogenic Escherichia coli.

1. Fairbrother, J., Nadeau, E., and Gyles, C. 2005. “Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies.” Anim. Health Res. Rev. 6(1): 17-39.

2. Keith Erlandson et al, “Characterization of nursery pig colibacillosis in a natural infection study.” Allen D. Leman Swine Conference 2015, Abstracts, Vol. 42, Pg. 32.

3. Guidance for Industry. Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern. Retrieved October 1, 2016 from https://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM052519.pdf

Kavault is a trademark of Eli Lilly and Company or its affiliates.